

**Table S5.** Antithrombotic treatment in patients with renal dysfunction (derivation cohort).

Variable	Patients with renal dysfunction (GFR <56 mL/min/1.73m <sup>2</sup> ) (n=250)			<i>p</i>
	All	Patients with LAA thrombus (n=30)	Patients without LAA thrombus (n=220)	
No OAC	15 (6%)	3 (10%)	12 (5%)	0.40
VKA	120 (48%)	13 (43%)	107 (49%)	0.84
NOAC	115 (46%)	14 (47%)	101 (46%)	0.84
- dabigatran	55 (22%)	10 (33%)	45 (20.5%)	0.16
- rivaroxaban	60 (24%)	4 (14%)	56 (25.5%)	0.25
- apixaban	0 (0%)	0 (0%)	0 (0%)	1.00
Antiplatelets	13 (5.2%)	2 (6.7%)	11 (5%)	0.66

GFR - glomerular filtration rate, LAA - left atrial appendage, NOAC - non-vitamin K antagonist oral anticoagulants, OAC - oral anticoagulation, VKA - vitamin K antagonists